No popular authors found.
Ads by Google:


No categories found.

Get's E-Newsletter

Ads by Google:

Follow / Share

Twitter Facebook Google Plus Pinterest RSS Podcast Email  Get Email Alerts

Popular Articles

No popular articles found. Sponsors:

Dr. Jennifer Sealey Voyksner

Jennifer has 30 years of experience in government and industry-based R&D. She is a pioneering mass spectrometrist focused on allergenic protein marker discovery and allergenic protein analysis. She is the CSO and co-founder of ImmunogenX™, a biopharmaceutical company focused on developing therapies and diagnostics for autoimmune and gastrointestinal diseases. Most recently, she was a co-founder and Director of R&D of LCMS Limited in North Carolina, an independent analytical laboratory.

Jennifer was diagnosed with celiac disease in 2002. This is an autoimmune disease related to ingestion of dietary gluten, for which there is no cure. She has since dedicated her professional and business career to bettering the lives of those who suffer from food-related diseases.

 Articles by this Author

Image: CC--Idaho National Laboratory

We are very pleased to provide an exciting update on our progress on bringing our therapeutic drug "latiglutenase" and our diagnostic disease management tool "CypCel" to market for patients suffering with celiac disease.

ImmunogenX is a clinical-stage company founded by dedicated scientists committed to bettering the lives of celiac disease patients. We are focused on celiac disease therapy, disease management and food safety. We acquired the assets of Alvine Pharmaceuticals in 2016 and are marching ahead with great confidence and enthusiasm and plan to start our final Phase 2 trial for latiglutenase later this year.